Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
No one on the platform currently holds RVNC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 459,300 | $2.4M |
No one on the platform has traded RVNC yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $RVNC investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗The $17M Revance Therapeutics ($RVNC) settlement deadline is August 28, 2026. If you bought shares between 2024 and 2025, you are likely eligible for the $17M recovery fund. This settlement resolves claims that Revance misled investors about its Teoxane partnership and the Crown acquisition. After the company disclosed problems with the Teoxane agreement, the acquisition price was cut from $6.66 to $3.10 per share, and investors sued. File your claim here: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗Imagine buying $RVNC at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $RVNC investors out there, we’ve got some important news: a $17 million investor settlement is now open for claims from shareholders who purchased shares between 2024 and 2025. The deadline is next months, you can check if you’re eligible and claim your share: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗$RVNC investors there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $RVNC investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗The $17.25M Revance Therapeutics ($RVNC) settlement deadline is August 28, 2026. If you purchased $RVNC shares between February 29, 2024 and December 6, 2024, you may be eligible. The case alleges Revance misled investors about its business performance and merger discussions with Crown Laboratories before the stock fell sharply. File your claim here: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗FAQ for $RVNC investors Q:What is this settlement about? A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer. Q: Who may qualify? A: Investors who purchased or acquired $RVNC securities between Feb. 29, 2024 and Feb. 6, 2025. Q: What’s the deadline? A: The claim deadline is Aug. 28, 2026. Q: What happened to the stock? A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share. Q: Is my data safe with 11th Estate? A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. Q: What is the fee? A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent. Q: How do I start? A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗The $17 million Revance Therapeutics ($RVNC) deadline is August 28, 2026 If you bought shares between February 29, 2024, and February 6, 2025, you are likely eligible for the $17 million recovery fund. This settlement resolves claims that Revance Therapeutics misled investors regarding its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.16 per share). File your claim here: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗@asssfhhwwws Yes, absolutely! Securities class action settlements in the U.S. (like the Revance Therapeutics case) are based on the stock you purchased, not where you live. If you bought $RVNC shares on a U.S. exchange (NASDAQ) through your Korean brokerage account during the class period, you are eligible to claim your share of the settlement.
View on StockTwits ↗$RVNC — Updates for the Revance Therapeutics investor settlement The settlement has just received preliminary approval, and you can already submit a claim to get payment. 📌 What happened? Revance allegedly misled investors about the strength and sustainability of its Teoxane partnership and overall sales performance. The issue came to light when a breach notice, stricter contract terms, and financial concerns were disclosed, leading to a reduced acquisition offer and significant pressure on the company’s outlook. ❓ Who qualifies? Buyers of $RVNC between February 29, 2024, and February 6, 2025, inclusive. ➡️ Apply now: https://11th.com/cases/revance-investor-settlement
View on StockTwits ↗
Wall St is expecting -0.30 EPS for $RVNC Q1 [Reporting 05/08 AMC] http://www.estimize.com/intro/rvnc?chart=historical&metric_name=eps&utm_c
View on StockTwits ↗
$RVNC I’m going to have a $TELL 2.0 delisting ceremony. I hope Foley has to sell his house like Souki.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $399M | +24.7% | $-0.22 | $-0.73–$0.19 | — | 4 |
| 2027 | $484M | +21.2% | $0.36 | $-1.42–$1.91 | 10.1× | 3 |
| 2028 | $574M | +18.8% | $0.86 | $0.86–$0.86 | 4.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-02-26 | $-0.29 | $-0.62 | -113.8% |
| 2024-11-07 | $-0.35 | $-0.37 | -5.7% |
| 2024-08-08 | $-0.48 | $-0.36 | +25.0% |
| 2024-05-09 | $-0.66 | $-0.54 | +18.2% |
| 2024-02-28 | $-0.79 | $-0.62 | +21.5% |
| 2023-11-08 | $-1.02 | $-0.74 | +27.5% |
| 2023-08-08 | $-0.72 | $-0.80 | -11.1% |
| 2023-05-09 | $-0.75 | $-0.74 | +1.3% |
| $676M |
| — |
| GTHXG1 Therapeutics, Inc. | $7.16 | +0.14% | $378M | — |
| ITOSiTeos Therapeutics, Inc. | $10.15 | +0.20% | $449M | — |
Source: Financial Modeling Prep · peers by sector/industry